lutetium-177
Commercial- Indications
- Cancer, Prostate Cancer, Neuroendocrine Tumors
Company intelligence / Profile preview
Eczacıbaşı’s healthcare division operates a large commercial portfolio in Turkey with both innovative/licensed-in medicines from global partners and its own generic drugs, food supplements, probiotics, vitamins/minerals, radiopharmaceuticals for diagnostics/therapy. The group resumed pharmaceutical manufacturing in Turkey with the acquisition of Gensenta in late-stage/commercial production. It also has a growing presence in nuclear medicine.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Eczacıbaşı.